PharVision Advisers’s Match Group MTCH Stock Holding History

PharVision Advisers’s Portfolio MTCH Stock Details MTCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,235	Closed	-$266K	–	446
2025 Q4	$266K	Buy	+8,235	New	+$271K	0.13%	351

Other funds holding MTCH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Starboard Value New York $4.52B AUM 19.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

PharVision Advisers's MTCH Position: Q1 2026 in Review

PharVision Advisers sold out of Match Group (MTCH) in Q1 2026, closing a stake of 8,235 shares — an estimated $266K sold.

PharVision Advisers first reported a position in MTCH in Q4 2025 and held it in 1 quarter. The position peaked at $266K in Q4 2025. 576 funds tracked by Wall St. Rank hold MTCH as of Q1 2026.

PharVision Advisers reported no remaining Match Group position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 8,235 Match Group shares in Q1 2026, an estimated $266K.
PharVision Advisers first reported a position in Match Group in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Match Group position peaked at $266K in Q4 2025.
576 funds tracked by Wall St. Rank held Match Group as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.